HRMY logo

Harmony Biosciences Holdings Inc. (HRMY)

$32.96

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on HRMY

Market cap

$1.94B

EPS

3.02

P/E ratio

13

Price to sales

2.44

Dividend yield

--

Beta

1.002215

Price on HRMY

Previous close

$33.76

Today's open

$33.78

Day's range

$32.87 - $34.01

52 week range

$25.90 - $43.49

Profile about HRMY

CEO

Jeffrey Dayno

Employees

293

Headquarters

Plymouth Meeting, PA

Exchange

NASDAQ Global Market

Shares outstanding

58723199

Issue type

Common Stock

HRMY industries and sectors

Healthcare

Biotechnology & Life Sciences

News on HRMY

HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix Growth

Harmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Harmony Biosciences Q3 Earnings Call Highlights

Harmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.

news source

MarketBeat • Nov 4, 2026

news preview

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript

Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 4, 2026

news preview

Harmony Biosciences Reports Q3 Financial Results on Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B

news source

GlobeNewsWire • Nov 4, 2026

news preview

Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag Estimates

Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.

news source

Zacks Investment Research • Nov 4, 2026

news preview

Harmony Biosciences Grapples With A Leadership Transition That Spooked Investors

Harmony Biosciences remains under pressure since the company announced its CEO transition. Will an upcoming narcolepsy drug change that?

news source

Investors Business Daily • Oct 28, 2026

news preview

Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings Growth

Harmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Oct 28, 2026

news preview

Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

news source

Zacks Investment Research • Oct 22, 2026

news preview

HRMY or ARGX: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?

news source

Zacks Investment Research • Oct 22, 2026

news preview

Revisiting Former Stock Picks Marriott, Logitech, Harmony Biosciences

Technical indicators have turned bullish for the Barron's Investor Circle stock picks.

news source

Barrons • Oct 22, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Harmony Biosciences Holdings Inc.

Open an M1 investment account to buy and sell Harmony Biosciences Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in HRMY on M1